Translations:SGLT2 inhibitor/5/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 19:46, 12 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (SGLT2 inhibitor)
A meta-analysis including 13 cardiovascular outcome trials found that SGLT-2 inhibitors reduce the risk for three-point [[Major adverse cardiovascular events|MACE]], especially in subjects with an [[estimated glomerular filtration rate]] (eGFR) below 60 ml/min, whereas [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] were more beneficial in persons with higher eGFR. Likewise, the risk reduction due to SGLT-2 inhibitors was larger in populations with a higher proportion of [[albuminuria]], but this relationship was not observed for GLP-1 receptor agonists. This suggests a differential use of the two substance classes in patients with preserved and reduced renal function or with and without [[diabetic nephropathy]], respectively.

A meta-analysis including 13 cardiovascular outcome trials found that SGLT-2 inhibitors reduce the risk for three-point MACE, especially in subjects with an estimated glomerular filtration rate (eGFR) below 60 ml/min, whereas GLP-1 receptor agonists were more beneficial in persons with higher eGFR. Likewise, the risk reduction due to SGLT-2 inhibitors was larger in populations with a higher proportion of albuminuria, but this relationship was not observed for GLP-1 receptor agonists. This suggests a differential use of the two substance classes in patients with preserved and reduced renal function or with and without diabetic nephropathy, respectively.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/5/en&oldid=113834"